Global iPSC-Derived Cardiomyocytes Market Growth 2026-2032
The global iPSC-Derived Cardiomyocytes market size is predicted to grow from US$ 852 million in 2025 to US$ 1726 million in 2032; it is expected to grow at a CAGR of 10.8% from 2026 to 2032.
iPSC-Derived Cardiomyocytes are human cardiomyocyte products generated through directed cardiac differentiation, purification, maturation, and quality control of induced pluripotent stem cells (iPSCs). They include ventricular-like, atrial-like, nodal-like, and mixed cardiomyocyte populations, and are typically supplied as cryopreserved cells, plate-ready cultures, or three-dimensional cardiac microtissues. These products are characterized by the expression of cardiac-specific biomarkers, spontaneous beating activity, action potential profiles, calcium transient dynamics, contractile force, batch-to-batch consistency, post-thaw viability, and validated sterility and mycoplasma-free status. They are widely used in cardiac safety assessment, drug screening, disease modeling, electrophysiological research, and early-stage regenerative medicine development. The overall gross margin is approximately 62%.
Demand for iPSC-derived cardiomyocytes is primarily driven by pharmaceutical companies and CROs seeking human-relevant cardiac models for drug safety evaluation. Conventional animal models and immortalized cell lines often fail to accurately reproduce human cardiac ion channel function, contractility, and genetic diversity. In contrast, iPSC-derived cardiomyocytes provide reproducible testing platforms compatible with multielectrode array (MEA), calcium imaging, patch-clamp electrophysiology, impedance measurement, and three-dimensional cardiac tissue models, making them well suited for early-stage drug discovery and preclinical cardiac risk assessment.
Product development is focused on well-defined cardiac subtypes, enhanced cellular maturation, improved batch consistency, and scalable manufacturing. Leading suppliers are expanding beyond standard cryopreserved cardiomyocytes to offer plate-ready cells, disease-specific models, isogenic control cell lines, and three-dimensional cardiac microtissues. These products are increasingly integrated with automated cell culture systems, functional assay platforms, and GMP-compatible manufacturing processes, enhancing their translational value for pharmaceutical research and regenerative medicine development.
Regional opportunities are concentrated in North America, Europe, and Japan, supported by continued investment in cardiovascular drug development, implementation of the CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative for cardiac safety evaluation, and expanding regenerative medicine research. Short-term challenges include incomplete cellular maturation, functional variability between production batches, relatively high product costs, and increasingly stringent quality control requirements. Nevertheless, continued advances in large-scale differentiation, cryopreservation technologies, and functional validation methods are expected to drive sustained growth in commercial adoption.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “iPSC-Derived Cardiomyocytes Industry Forecast” looks at past sales and reviews total world iPSC-Derived Cardiomyocytes sales in 2025, providing a comprehensive analysis by region and market sector of projected iPSC-Derived Cardiomyocytes sales for 2026 through 2032. With iPSC-Derived Cardiomyocytes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world iPSC-Derived Cardiomyocytes industry.
This Insight Report provides a comprehensive analysis of the global iPSC-Derived Cardiomyocytes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on iPSC-Derived Cardiomyocytes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global iPSC-Derived Cardiomyocytes market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for iPSC-Derived Cardiomyocytes and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global iPSC-Derived Cardiomyocytes.
This report presents a comprehensive overview, market shares, and growth opportunities of iPSC-Derived Cardiomyocytes market by product type, application, key manufacturers and key regions and countries.
iPSC-Derived Cardiomyocytes are human cardiomyocyte products generated through directed cardiac differentiation, purification, maturation, and quality control of induced pluripotent stem cells (iPSCs). They include ventricular-like, atrial-like, nodal-like, and mixed cardiomyocyte populations, and are typically supplied as cryopreserved cells, plate-ready cultures, or three-dimensional cardiac microtissues. These products are characterized by the expression of cardiac-specific biomarkers, spontaneous beating activity, action potential profiles, calcium transient dynamics, contractile force, batch-to-batch consistency, post-thaw viability, and validated sterility and mycoplasma-free status. They are widely used in cardiac safety assessment, drug screening, disease modeling, electrophysiological research, and early-stage regenerative medicine development. The overall gross margin is approximately 62%.
Demand for iPSC-derived cardiomyocytes is primarily driven by pharmaceutical companies and CROs seeking human-relevant cardiac models for drug safety evaluation. Conventional animal models and immortalized cell lines often fail to accurately reproduce human cardiac ion channel function, contractility, and genetic diversity. In contrast, iPSC-derived cardiomyocytes provide reproducible testing platforms compatible with multielectrode array (MEA), calcium imaging, patch-clamp electrophysiology, impedance measurement, and three-dimensional cardiac tissue models, making them well suited for early-stage drug discovery and preclinical cardiac risk assessment.
Product development is focused on well-defined cardiac subtypes, enhanced cellular maturation, improved batch consistency, and scalable manufacturing. Leading suppliers are expanding beyond standard cryopreserved cardiomyocytes to offer plate-ready cells, disease-specific models, isogenic control cell lines, and three-dimensional cardiac microtissues. These products are increasingly integrated with automated cell culture systems, functional assay platforms, and GMP-compatible manufacturing processes, enhancing their translational value for pharmaceutical research and regenerative medicine development.
Regional opportunities are concentrated in North America, Europe, and Japan, supported by continued investment in cardiovascular drug development, implementation of the CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative for cardiac safety evaluation, and expanding regenerative medicine research. Short-term challenges include incomplete cellular maturation, functional variability between production batches, relatively high product costs, and increasingly stringent quality control requirements. Nevertheless, continued advances in large-scale differentiation, cryopreservation technologies, and functional validation methods are expected to drive sustained growth in commercial adoption.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “iPSC-Derived Cardiomyocytes Industry Forecast” looks at past sales and reviews total world iPSC-Derived Cardiomyocytes sales in 2025, providing a comprehensive analysis by region and market sector of projected iPSC-Derived Cardiomyocytes sales for 2026 through 2032. With iPSC-Derived Cardiomyocytes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world iPSC-Derived Cardiomyocytes industry.
This Insight Report provides a comprehensive analysis of the global iPSC-Derived Cardiomyocytes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on iPSC-Derived Cardiomyocytes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global iPSC-Derived Cardiomyocytes market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for iPSC-Derived Cardiomyocytes and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global iPSC-Derived Cardiomyocytes.
This report presents a comprehensive overview, market shares, and growth opportunities of iPSC-Derived Cardiomyocytes market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Ventricular-Like Cardiomyocytes
- Atrial-Like Cardiomyocytes
- Nodal-Like Cardiomyocytes
- Mixed Cardiomyocytes
- Cardiac Progenitor-Derived Cardiomyocytes
Segmentation by Donor and Genetic Background:
- Healthy Donor Cells
- Patient-Derived Disease Cells
- Gene-Edited Disease Cells
- Isogenic Control Cells
- Custom Line-Derived Cells
Segmentation by Delivery Format:
- Cryopreserved Cell Vials
- Plate-Ready Cells
- Assay Kits With Media
- 3D Cardiac Microtissues
- Custom Differentiation Lots
Segmentation by Validation Grade:
- Standard Research Grade
- Assay-Ready Grade
- Electrophysiology Validated Grade
- High-Throughput Screening Grade
- GMP-Compatible Development Grade
Segmentation by Application:
- Cardiotoxicity Testing
- Drug Discovery and Screening
- Disease Modeling
- Electrophysiology and Contractility Assays
- Regenerative Medicine Research
- Cardiac Tissue Engineering
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- FUJIFILM Cellular Dynamics
- Ncardia
- Axol Bioscience
- REPROCELL
- NEXEL
- Curi Bio
- Creative Bioarray
- Applied StemCell
- BPS Bioscience
- Cell Applications
Key Questions Addressed in this Report
- What is the 10-year outlook for the global iPSC-Derived Cardiomyocytes market?
- What factors are driving iPSC-Derived Cardiomyocytes market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do iPSC-Derived Cardiomyocytes market opportunities vary by end market size?
- How does iPSC-Derived Cardiomyocytes break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global iPSC-Derived Cardiomyocytes Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for iPSC-Derived Cardiomyocytes by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for iPSC-Derived Cardiomyocytes by Country/Region, 2021, 2025 & 2032
2.2 iPSC-Derived Cardiomyocytes Segment by Type
2.2.1 Ventricular-Like Cardiomyocytes
2.2.2 Atrial-Like Cardiomyocytes
2.2.3 Nodal-Like Cardiomyocytes
2.2.4 Mixed Cardiomyocytes
2.2.5 Cardiac Progenitor-Derived Cardiomyocytes
2.2.6 iPSC-Derived Cardiomyocytes Sales by Type
2.2.6.1 Global iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
2.2.6.2 Global iPSC-Derived Cardiomyocytes Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global iPSC-Derived Cardiomyocytes Sale Price by Type (2021-2026)
2.3 iPSC-Derived Cardiomyocytes Segment by Donor and Genetic Background
2.3.1 Healthy Donor Cells
2.3.2 Patient-Derived Disease Cells
2.3.3 Gene-Edited Disease Cells
2.3.4 Isogenic Control Cells
2.3.5 Custom Line-Derived Cells
2.3.6 iPSC-Derived Cardiomyocytes Sales by Donor and Genetic Background
2.3.6.1 Global iPSC-Derived Cardiomyocytes Sales Market Share by Donor and Genetic Background (2021-2026)
2.3.6.2 Global iPSC-Derived Cardiomyocytes Revenue and Market Share by Donor and Genetic Background (2021-2026)
2.3.6.3 Global iPSC-Derived Cardiomyocytes Sale Price by Donor and Genetic Background (2021-2026)
2.4 iPSC-Derived Cardiomyocytes Segment by Delivery Format
2.4.1 Cryopreserved Cell Vials
2.4.2 Plate-Ready Cells
2.4.3 Assay Kits With Media
2.4.4 3D Cardiac Microtissues
2.4.5 Custom Differentiation Lots
2.4.6 iPSC-Derived Cardiomyocytes Sales by Delivery Format
2.4.6.1 Global iPSC-Derived Cardiomyocytes Sales Market Share by Delivery Format (2021-2026)
2.4.6.2 Global iPSC-Derived Cardiomyocytes Revenue and Market Share by Delivery Format (2021-2026)
2.4.6.3 Global iPSC-Derived Cardiomyocytes Sale Price by Delivery Format (2021-2026)
2.5 iPSC-Derived Cardiomyocytes Segment by Validation Grade
2.5.1 Standard Research Grade
2.5.2 Assay-Ready Grade
2.5.3 Electrophysiology Validated Grade
2.5.4 High-Throughput Screening Grade
2.5.5 GMP-Compatible Development Grade
2.5.6 iPSC-Derived Cardiomyocytes Sales by Validation Grade
2.5.6.1 Global iPSC-Derived Cardiomyocytes Sales Market Share by Validation Grade (2021-2026)
2.5.6.2 Global iPSC-Derived Cardiomyocytes Revenue and Market Share by Validation Grade (2021-2026)
2.5.6.3 Global iPSC-Derived Cardiomyocytes Sale Price by Validation Grade (2021-2026)
2.6 iPSC-Derived Cardiomyocytes Segment by Application
2.6.1 Cardiotoxicity Testing
2.6.2 Drug Discovery and Screening
2.6.3 Disease Modeling
2.6.4 Electrophysiology and Contractility Assays
2.6.5 Regenerative Medicine Research
2.6.6 Cardiac Tissue Engineering
2.6.7 iPSC-Derived Cardiomyocytes Sales by Application
2.6.7.1 Global iPSC-Derived Cardiomyocytes Sale Market Share by Application (2021-2026)
2.6.7.2 Global iPSC-Derived Cardiomyocytes Revenue and Market Share by Application (2021-2026)
2.6.7.3 Global iPSC-Derived Cardiomyocytes Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global iPSC-Derived Cardiomyocytes Breakdown Data by Company
3.1.1 Global iPSC-Derived Cardiomyocytes Annual Sales by Company (2021-2026)
3.1.2 Global iPSC-Derived Cardiomyocytes Sales Market Share by Company (2021-2026)
3.2 Global iPSC-Derived Cardiomyocytes Annual Revenue by Company (2021-2026)
3.2.1 Global iPSC-Derived Cardiomyocytes Revenue by Company (2021-2026)
3.2.2 Global iPSC-Derived Cardiomyocytes Revenue Market Share by Company (2021-2026)
3.3 Global iPSC-Derived Cardiomyocytes Sale Price by Company
3.4 Key Manufacturers iPSC-Derived Cardiomyocytes Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers iPSC-Derived Cardiomyocytes Product Location Distribution
3.4.2 Players iPSC-Derived Cardiomyocytes Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IPSC-DERIVED CARDIOMYOCYTES BY GEOGRAPHIC REGION
4.1 World Historic iPSC-Derived Cardiomyocytes Market Size by Geographic Region (2021-2026)
4.1.1 Global iPSC-Derived Cardiomyocytes Annual Sales by Geographic Region (2021-2026)
4.1.2 Global iPSC-Derived Cardiomyocytes Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic iPSC-Derived Cardiomyocytes Market Size by Country/Region (2021-2026)
4.2.1 Global iPSC-Derived Cardiomyocytes Annual Sales by Country/Region (2021-2026)
4.2.2 Global iPSC-Derived Cardiomyocytes Annual Revenue by Country/Region (2021-2026)
4.3 Americas iPSC-Derived Cardiomyocytes Sales Growth
4.4 APAC iPSC-Derived Cardiomyocytes Sales Growth
4.5 Europe iPSC-Derived Cardiomyocytes Sales Growth
4.6 Middle East & Africa iPSC-Derived Cardiomyocytes Sales Growth
5 AMERICAS
5.1 Americas iPSC-Derived Cardiomyocytes Sales by Country
5.1.1 Americas iPSC-Derived Cardiomyocytes Sales by Country (2021-2026)
5.1.2 Americas iPSC-Derived Cardiomyocytes Revenue by Country (2021-2026)
5.2 Americas iPSC-Derived Cardiomyocytes Sales by Type (2021-2026)
5.3 Americas iPSC-Derived Cardiomyocytes Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC iPSC-Derived Cardiomyocytes Sales by Region
6.1.1 APAC iPSC-Derived Cardiomyocytes Sales by Region (2021-2026)
6.1.2 APAC iPSC-Derived Cardiomyocytes Revenue by Region (2021-2026)
6.2 APAC iPSC-Derived Cardiomyocytes Sales by Type (2021-2026)
6.3 APAC iPSC-Derived Cardiomyocytes Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe iPSC-Derived Cardiomyocytes by Country
7.1.1 Europe iPSC-Derived Cardiomyocytes Sales by Country (2021-2026)
7.1.2 Europe iPSC-Derived Cardiomyocytes Revenue by Country (2021-2026)
7.2 Europe iPSC-Derived Cardiomyocytes Sales by Type (2021-2026)
7.3 Europe iPSC-Derived Cardiomyocytes Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa iPSC-Derived Cardiomyocytes by Country
8.1.1 Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Country (2021-2026)
8.1.2 Middle East & Africa iPSC-Derived Cardiomyocytes Revenue by Country (2021-2026)
8.2 Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Type (2021-2026)
8.3 Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of iPSC-Derived Cardiomyocytes
10.3 Manufacturing Process Analysis of iPSC-Derived Cardiomyocytes
10.4 Industry Chain Structure of iPSC-Derived Cardiomyocytes
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 iPSC-Derived Cardiomyocytes Distributors
11.3 iPSC-Derived Cardiomyocytes Customer
12 WORLD FORECAST REVIEW FOR IPSC-DERIVED CARDIOMYOCYTES BY GEOGRAPHIC REGION
12.1 Global iPSC-Derived Cardiomyocytes Market Size Forecast by Region
12.1.1 Global iPSC-Derived Cardiomyocytes Forecast by Region (2027-2032)
12.1.2 Global iPSC-Derived Cardiomyocytes Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global iPSC-Derived Cardiomyocytes Forecast by Type (2027-2032)
12.7 Global iPSC-Derived Cardiomyocytes Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 FUJIFILM Cellular Dynamics
13.1.1 FUJIFILM Cellular Dynamics Company Information
13.1.2 FUJIFILM Cellular Dynamics iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.1.3 FUJIFILM Cellular Dynamics iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 FUJIFILM Cellular Dynamics Main Business Overview
13.1.5 FUJIFILM Cellular Dynamics Latest Developments
13.2 Ncardia
13.2.1 Ncardia Company Information
13.2.2 Ncardia iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.2.3 Ncardia iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Ncardia Main Business Overview
13.2.5 Ncardia Latest Developments
13.3 Axol Bioscience
13.3.1 Axol Bioscience Company Information
13.3.2 Axol Bioscience iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.3.3 Axol Bioscience iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Axol Bioscience Main Business Overview
13.3.5 Axol Bioscience Latest Developments
13.4 REPROCELL
13.4.1 REPROCELL Company Information
13.4.2 REPROCELL iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.4.3 REPROCELL iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 REPROCELL Main Business Overview
13.4.5 REPROCELL Latest Developments
13.5 NEXEL
13.5.1 NEXEL Company Information
13.5.2 NEXEL iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.5.3 NEXEL iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 NEXEL Main Business Overview
13.5.5 NEXEL Latest Developments
13.6 Curi Bio
13.6.1 Curi Bio Company Information
13.6.2 Curi Bio iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.6.3 Curi Bio iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Curi Bio Main Business Overview
13.6.5 Curi Bio Latest Developments
13.7 Creative Bioarray
13.7.1 Creative Bioarray Company Information
13.7.2 Creative Bioarray iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.7.3 Creative Bioarray iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Creative Bioarray Main Business Overview
13.7.5 Creative Bioarray Latest Developments
13.8 Applied StemCell
13.8.1 Applied StemCell Company Information
13.8.2 Applied StemCell iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.8.3 Applied StemCell iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Applied StemCell Main Business Overview
13.8.5 Applied StemCell Latest Developments
13.9 BPS Bioscience
13.9.1 BPS Bioscience Company Information
13.9.2 BPS Bioscience iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.9.3 BPS Bioscience iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 BPS Bioscience Main Business Overview
13.9.5 BPS Bioscience Latest Developments
13.10 Cell Applications
13.10.1 Cell Applications Company Information
13.10.2 Cell Applications iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.10.3 Cell Applications iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Cell Applications Main Business Overview
13.10.5 Cell Applications Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global iPSC-Derived Cardiomyocytes Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for iPSC-Derived Cardiomyocytes by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for iPSC-Derived Cardiomyocytes by Country/Region, 2021, 2025 & 2032
2.2 iPSC-Derived Cardiomyocytes Segment by Type
2.2.1 Ventricular-Like Cardiomyocytes
2.2.2 Atrial-Like Cardiomyocytes
2.2.3 Nodal-Like Cardiomyocytes
2.2.4 Mixed Cardiomyocytes
2.2.5 Cardiac Progenitor-Derived Cardiomyocytes
2.2.6 iPSC-Derived Cardiomyocytes Sales by Type
2.2.6.1 Global iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
2.2.6.2 Global iPSC-Derived Cardiomyocytes Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global iPSC-Derived Cardiomyocytes Sale Price by Type (2021-2026)
2.3 iPSC-Derived Cardiomyocytes Segment by Donor and Genetic Background
2.3.1 Healthy Donor Cells
2.3.2 Patient-Derived Disease Cells
2.3.3 Gene-Edited Disease Cells
2.3.4 Isogenic Control Cells
2.3.5 Custom Line-Derived Cells
2.3.6 iPSC-Derived Cardiomyocytes Sales by Donor and Genetic Background
2.3.6.1 Global iPSC-Derived Cardiomyocytes Sales Market Share by Donor and Genetic Background (2021-2026)
2.3.6.2 Global iPSC-Derived Cardiomyocytes Revenue and Market Share by Donor and Genetic Background (2021-2026)
2.3.6.3 Global iPSC-Derived Cardiomyocytes Sale Price by Donor and Genetic Background (2021-2026)
2.4 iPSC-Derived Cardiomyocytes Segment by Delivery Format
2.4.1 Cryopreserved Cell Vials
2.4.2 Plate-Ready Cells
2.4.3 Assay Kits With Media
2.4.4 3D Cardiac Microtissues
2.4.5 Custom Differentiation Lots
2.4.6 iPSC-Derived Cardiomyocytes Sales by Delivery Format
2.4.6.1 Global iPSC-Derived Cardiomyocytes Sales Market Share by Delivery Format (2021-2026)
2.4.6.2 Global iPSC-Derived Cardiomyocytes Revenue and Market Share by Delivery Format (2021-2026)
2.4.6.3 Global iPSC-Derived Cardiomyocytes Sale Price by Delivery Format (2021-2026)
2.5 iPSC-Derived Cardiomyocytes Segment by Validation Grade
2.5.1 Standard Research Grade
2.5.2 Assay-Ready Grade
2.5.3 Electrophysiology Validated Grade
2.5.4 High-Throughput Screening Grade
2.5.5 GMP-Compatible Development Grade
2.5.6 iPSC-Derived Cardiomyocytes Sales by Validation Grade
2.5.6.1 Global iPSC-Derived Cardiomyocytes Sales Market Share by Validation Grade (2021-2026)
2.5.6.2 Global iPSC-Derived Cardiomyocytes Revenue and Market Share by Validation Grade (2021-2026)
2.5.6.3 Global iPSC-Derived Cardiomyocytes Sale Price by Validation Grade (2021-2026)
2.6 iPSC-Derived Cardiomyocytes Segment by Application
2.6.1 Cardiotoxicity Testing
2.6.2 Drug Discovery and Screening
2.6.3 Disease Modeling
2.6.4 Electrophysiology and Contractility Assays
2.6.5 Regenerative Medicine Research
2.6.6 Cardiac Tissue Engineering
2.6.7 iPSC-Derived Cardiomyocytes Sales by Application
2.6.7.1 Global iPSC-Derived Cardiomyocytes Sale Market Share by Application (2021-2026)
2.6.7.2 Global iPSC-Derived Cardiomyocytes Revenue and Market Share by Application (2021-2026)
2.6.7.3 Global iPSC-Derived Cardiomyocytes Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global iPSC-Derived Cardiomyocytes Breakdown Data by Company
3.1.1 Global iPSC-Derived Cardiomyocytes Annual Sales by Company (2021-2026)
3.1.2 Global iPSC-Derived Cardiomyocytes Sales Market Share by Company (2021-2026)
3.2 Global iPSC-Derived Cardiomyocytes Annual Revenue by Company (2021-2026)
3.2.1 Global iPSC-Derived Cardiomyocytes Revenue by Company (2021-2026)
3.2.2 Global iPSC-Derived Cardiomyocytes Revenue Market Share by Company (2021-2026)
3.3 Global iPSC-Derived Cardiomyocytes Sale Price by Company
3.4 Key Manufacturers iPSC-Derived Cardiomyocytes Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers iPSC-Derived Cardiomyocytes Product Location Distribution
3.4.2 Players iPSC-Derived Cardiomyocytes Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IPSC-DERIVED CARDIOMYOCYTES BY GEOGRAPHIC REGION
4.1 World Historic iPSC-Derived Cardiomyocytes Market Size by Geographic Region (2021-2026)
4.1.1 Global iPSC-Derived Cardiomyocytes Annual Sales by Geographic Region (2021-2026)
4.1.2 Global iPSC-Derived Cardiomyocytes Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic iPSC-Derived Cardiomyocytes Market Size by Country/Region (2021-2026)
4.2.1 Global iPSC-Derived Cardiomyocytes Annual Sales by Country/Region (2021-2026)
4.2.2 Global iPSC-Derived Cardiomyocytes Annual Revenue by Country/Region (2021-2026)
4.3 Americas iPSC-Derived Cardiomyocytes Sales Growth
4.4 APAC iPSC-Derived Cardiomyocytes Sales Growth
4.5 Europe iPSC-Derived Cardiomyocytes Sales Growth
4.6 Middle East & Africa iPSC-Derived Cardiomyocytes Sales Growth
5 AMERICAS
5.1 Americas iPSC-Derived Cardiomyocytes Sales by Country
5.1.1 Americas iPSC-Derived Cardiomyocytes Sales by Country (2021-2026)
5.1.2 Americas iPSC-Derived Cardiomyocytes Revenue by Country (2021-2026)
5.2 Americas iPSC-Derived Cardiomyocytes Sales by Type (2021-2026)
5.3 Americas iPSC-Derived Cardiomyocytes Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC iPSC-Derived Cardiomyocytes Sales by Region
6.1.1 APAC iPSC-Derived Cardiomyocytes Sales by Region (2021-2026)
6.1.2 APAC iPSC-Derived Cardiomyocytes Revenue by Region (2021-2026)
6.2 APAC iPSC-Derived Cardiomyocytes Sales by Type (2021-2026)
6.3 APAC iPSC-Derived Cardiomyocytes Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe iPSC-Derived Cardiomyocytes by Country
7.1.1 Europe iPSC-Derived Cardiomyocytes Sales by Country (2021-2026)
7.1.2 Europe iPSC-Derived Cardiomyocytes Revenue by Country (2021-2026)
7.2 Europe iPSC-Derived Cardiomyocytes Sales by Type (2021-2026)
7.3 Europe iPSC-Derived Cardiomyocytes Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa iPSC-Derived Cardiomyocytes by Country
8.1.1 Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Country (2021-2026)
8.1.2 Middle East & Africa iPSC-Derived Cardiomyocytes Revenue by Country (2021-2026)
8.2 Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Type (2021-2026)
8.3 Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of iPSC-Derived Cardiomyocytes
10.3 Manufacturing Process Analysis of iPSC-Derived Cardiomyocytes
10.4 Industry Chain Structure of iPSC-Derived Cardiomyocytes
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 iPSC-Derived Cardiomyocytes Distributors
11.3 iPSC-Derived Cardiomyocytes Customer
12 WORLD FORECAST REVIEW FOR IPSC-DERIVED CARDIOMYOCYTES BY GEOGRAPHIC REGION
12.1 Global iPSC-Derived Cardiomyocytes Market Size Forecast by Region
12.1.1 Global iPSC-Derived Cardiomyocytes Forecast by Region (2027-2032)
12.1.2 Global iPSC-Derived Cardiomyocytes Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global iPSC-Derived Cardiomyocytes Forecast by Type (2027-2032)
12.7 Global iPSC-Derived Cardiomyocytes Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 FUJIFILM Cellular Dynamics
13.1.1 FUJIFILM Cellular Dynamics Company Information
13.1.2 FUJIFILM Cellular Dynamics iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.1.3 FUJIFILM Cellular Dynamics iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 FUJIFILM Cellular Dynamics Main Business Overview
13.1.5 FUJIFILM Cellular Dynamics Latest Developments
13.2 Ncardia
13.2.1 Ncardia Company Information
13.2.2 Ncardia iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.2.3 Ncardia iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Ncardia Main Business Overview
13.2.5 Ncardia Latest Developments
13.3 Axol Bioscience
13.3.1 Axol Bioscience Company Information
13.3.2 Axol Bioscience iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.3.3 Axol Bioscience iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Axol Bioscience Main Business Overview
13.3.5 Axol Bioscience Latest Developments
13.4 REPROCELL
13.4.1 REPROCELL Company Information
13.4.2 REPROCELL iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.4.3 REPROCELL iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 REPROCELL Main Business Overview
13.4.5 REPROCELL Latest Developments
13.5 NEXEL
13.5.1 NEXEL Company Information
13.5.2 NEXEL iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.5.3 NEXEL iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 NEXEL Main Business Overview
13.5.5 NEXEL Latest Developments
13.6 Curi Bio
13.6.1 Curi Bio Company Information
13.6.2 Curi Bio iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.6.3 Curi Bio iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Curi Bio Main Business Overview
13.6.5 Curi Bio Latest Developments
13.7 Creative Bioarray
13.7.1 Creative Bioarray Company Information
13.7.2 Creative Bioarray iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.7.3 Creative Bioarray iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Creative Bioarray Main Business Overview
13.7.5 Creative Bioarray Latest Developments
13.8 Applied StemCell
13.8.1 Applied StemCell Company Information
13.8.2 Applied StemCell iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.8.3 Applied StemCell iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Applied StemCell Main Business Overview
13.8.5 Applied StemCell Latest Developments
13.9 BPS Bioscience
13.9.1 BPS Bioscience Company Information
13.9.2 BPS Bioscience iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.9.3 BPS Bioscience iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 BPS Bioscience Main Business Overview
13.9.5 BPS Bioscience Latest Developments
13.10 Cell Applications
13.10.1 Cell Applications Company Information
13.10.2 Cell Applications iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
13.10.3 Cell Applications iPSC-Derived Cardiomyocytes Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Cell Applications Main Business Overview
13.10.5 Cell Applications Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. iPSC-Derived Cardiomyocytes Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. iPSC-Derived Cardiomyocytes Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Ventricular-Like Cardiomyocytes
Table 4. Major Players of Atrial-Like Cardiomyocytes
Table 5. Major Players of Nodal-Like Cardiomyocytes
Table 6. Major Players of Mixed Cardiomyocytes
Table 7. Major Players of Cardiac Progenitor-Derived Cardiomyocytes
Table 8. Global iPSC-Derived Cardiomyocytes Sales by Type (2021-2026) & (K Dose)
Table 9. Global iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
Table 10. Global iPSC-Derived Cardiomyocytes Revenue by Type (2021-2026) & ($ million)
Table 11. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Type (2021-2026)
Table 12. Global iPSC-Derived Cardiomyocytes Sale Price by Type (2021-2026) & (US$/Dose)
Table 13. Major Players of Healthy Donor Cells
Table 14. Major Players of Patient-Derived Disease Cells
Table 15. Major Players of Gene-Edited Disease Cells
Table 16. Major Players of Isogenic Control Cells
Table 17. Major Players of Custom Line-Derived Cells
Table 18. Global iPSC-Derived Cardiomyocytes Sales by Donor and Genetic Background (2021-2026) & (K Dose)
Table 19. Global iPSC-Derived Cardiomyocytes Sales Market Share by Donor and Genetic Background (2021-2026)
Table 20. Global iPSC-Derived Cardiomyocytes Revenue by Donor and Genetic Background (2021-2026) & ($ million)
Table 21. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Donor and Genetic Background (2021-2026)
Table 22. Global iPSC-Derived Cardiomyocytes Sale Price by Donor and Genetic Background (2021-2026) & (US$/Dose)
Table 23. Major Players of Cryopreserved Cell Vials
Table 24. Major Players of Plate-Ready Cells
Table 25. Major Players of Assay Kits With Media
Table 26. Major Players of 3D Cardiac Microtissues
Table 27. Major Players of Custom Differentiation Lots
Table 28. Global iPSC-Derived Cardiomyocytes Sales by Delivery Format (2021-2026) & (K Dose)
Table 29. Global iPSC-Derived Cardiomyocytes Sales Market Share by Delivery Format (2021-2026)
Table 30. Global iPSC-Derived Cardiomyocytes Revenue by Delivery Format (2021-2026) & ($ million)
Table 31. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Delivery Format (2021-2026)
Table 32. Global iPSC-Derived Cardiomyocytes Sale Price by Delivery Format (2021-2026) & (US$/Dose)
Table 33. Major Players of Standard Research Grade
Table 34. Major Players of Assay-Ready Grade
Table 35. Major Players of Electrophysiology Validated Grade
Table 36. Major Players of High-Throughput Screening Grade
Table 37. Major Players of GMP-Compatible Development Grade
Table 38. Global iPSC-Derived Cardiomyocytes Sales by Validation Grade (2021-2026) & (K Dose)
Table 39. Global iPSC-Derived Cardiomyocytes Sales Market Share by Validation Grade (2021-2026)
Table 40. Global iPSC-Derived Cardiomyocytes Revenue by Validation Grade (2021-2026) & ($ million)
Table 41. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Validation Grade (2021-2026)
Table 42. Global iPSC-Derived Cardiomyocytes Sale Price by Validation Grade (2021-2026) & (US$/Dose)
Table 43. Global iPSC-Derived Cardiomyocytes Sale by Application (2021-2026) & (K Dose)
Table 44. Global iPSC-Derived Cardiomyocytes Sale Market Share by Application (2021-2026)
Table 45. Global iPSC-Derived Cardiomyocytes Revenue by Application (2021-2026) & ($ million)
Table 46. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Application (2021-2026)
Table 47. Global iPSC-Derived Cardiomyocytes Sale Price by Application (2021-2026) & (US$/Dose)
Table 48. Global iPSC-Derived Cardiomyocytes Sales by Company (2021-2026) & (K Dose)
Table 49. Global iPSC-Derived Cardiomyocytes Sales Market Share by Company (2021-2026)
Table 50. Global iPSC-Derived Cardiomyocytes Revenue by Company (2021-2026) & ($ millions)
Table 51. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Company (2021-2026)
Table 52. Global iPSC-Derived Cardiomyocytes Sale Price by Company (2021-2026) & (US$/Dose)
Table 53. Key Manufacturers iPSC-Derived Cardiomyocytes Producing Area Distribution and Sales Area
Table 54. Players iPSC-Derived Cardiomyocytes Products Offered
Table 55. iPSC-Derived Cardiomyocytes Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 56. New Products and Potential Entrants
Table 57. Market M&A Activity & Strategy
Table 58. Global iPSC-Derived Cardiomyocytes Sales by Geographic Region (2021-2026) & (K Dose)
Table 59. Global iPSC-Derived Cardiomyocytes Sales Market Share Geographic Region (2021-2026)
Table 60. Global iPSC-Derived Cardiomyocytes Revenue by Geographic Region (2021-2026) & ($ millions)
Table 61. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Geographic Region (2021-2026)
Table 62. Global iPSC-Derived Cardiomyocytes Sales by Country/Region (2021-2026) & (K Dose)
Table 63. Global iPSC-Derived Cardiomyocytes Sales Market Share by Country/Region (2021-2026)
Table 64. Global iPSC-Derived Cardiomyocytes Revenue by Country/Region (2021-2026) & ($ millions)
Table 65. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Country/Region (2021-2026)
Table 66. Americas iPSC-Derived Cardiomyocytes Sales by Country (2021-2026) & (K Dose)
Table 67. Americas iPSC-Derived Cardiomyocytes Sales Market Share by Country (2021-2026)
Table 68. Americas iPSC-Derived Cardiomyocytes Revenue by Country (2021-2026) & ($ millions)
Table 69. Americas iPSC-Derived Cardiomyocytes Sales by Type (2021-2026) & (K Dose)
Table 70. Americas iPSC-Derived Cardiomyocytes Sales by Application (2021-2026) & (K Dose)
Table 71. APAC iPSC-Derived Cardiomyocytes Sales by Region (2021-2026) & (K Dose)
Table 72. APAC iPSC-Derived Cardiomyocytes Sales Market Share by Region (2021-2026)
Table 73. APAC iPSC-Derived Cardiomyocytes Revenue by Region (2021-2026) & ($ millions)
Table 74. APAC iPSC-Derived Cardiomyocytes Sales by Type (2021-2026) & (K Dose)
Table 75. APAC iPSC-Derived Cardiomyocytes Sales by Application (2021-2026) & (K Dose)
Table 76. Europe iPSC-Derived Cardiomyocytes Sales by Country (2021-2026) & (K Dose)
Table 77. Europe iPSC-Derived Cardiomyocytes Revenue by Country (2021-2026) & ($ millions)
Table 78. Europe iPSC-Derived Cardiomyocytes Sales by Type (2021-2026) & (K Dose)
Table 79. Europe iPSC-Derived Cardiomyocytes Sales by Application (2021-2026) & (K Dose)
Table 80. Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Country (2021-2026) & (K Dose)
Table 81. Middle East & Africa iPSC-Derived Cardiomyocytes Revenue Market Share by Country (2021-2026)
Table 82. Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Type (2021-2026) & (K Dose)
Table 83. Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Application (2021-2026) & (K Dose)
Table 84. Key Market Drivers & Growth Opportunities of iPSC-Derived Cardiomyocytes
Table 85. Key Market Challenges & Risks of iPSC-Derived Cardiomyocytes
Table 86. Key Industry Trends of iPSC-Derived Cardiomyocytes
Table 87. iPSC-Derived Cardiomyocytes Raw Material
Table 88. Key Suppliers of Raw Materials
Table 89. iPSC-Derived Cardiomyocytes Distributors List
Table 90. iPSC-Derived Cardiomyocytes Customer List
Table 91. Global iPSC-Derived Cardiomyocytes Sales Forecast by Region (2027-2032) & (K Dose)
Table 92. Global iPSC-Derived Cardiomyocytes Revenue Forecast by Region (2027-2032) & ($ millions)
Table 93. Americas iPSC-Derived Cardiomyocytes Sales Forecast by Country (2027-2032) & (K Dose)
Table 94. Americas iPSC-Derived Cardiomyocytes Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 95. APAC iPSC-Derived Cardiomyocytes Sales Forecast by Region (2027-2032) & (K Dose)
Table 96. APAC iPSC-Derived Cardiomyocytes Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 97. Europe iPSC-Derived Cardiomyocytes Sales Forecast by Country (2027-2032) & (K Dose)
Table 98. Europe iPSC-Derived Cardiomyocytes Revenue Forecast by Country (2027-2032) & ($ millions)
Table 99. Middle East & Africa iPSC-Derived Cardiomyocytes Sales Forecast by Country (2027-2032) & (K Dose)
Table 100. Middle East & Africa iPSC-Derived Cardiomyocytes Revenue Forecast by Country (2027-2032) & ($ millions)
Table 101. Global iPSC-Derived Cardiomyocytes Sales Forecast by Type (2027-2032) & (K Dose)
Table 102. Global iPSC-Derived Cardiomyocytes Revenue Forecast by Type (2027-2032) & ($ millions)
Table 103. Global iPSC-Derived Cardiomyocytes Sales Forecast by Application (2027-2032) & (K Dose)
Table 104. Global iPSC-Derived Cardiomyocytes Revenue Forecast by Application (2027-2032) & ($ millions)
Table 105. FUJIFILM Cellular Dynamics Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 106. FUJIFILM Cellular Dynamics iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 107. FUJIFILM Cellular Dynamics iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. FUJIFILM Cellular Dynamics Main Business
Table 109. FUJIFILM Cellular Dynamics Latest Developments
Table 110. Ncardia Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 111. Ncardia iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 112. Ncardia iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 113. Ncardia Main Business
Table 114. Ncardia Latest Developments
Table 115. Axol Bioscience Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 116. Axol Bioscience iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 117. Axol Bioscience iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 118. Axol Bioscience Main Business
Table 119. Axol Bioscience Latest Developments
Table 120. REPROCELL Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 121. REPROCELL iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 122. REPROCELL iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 123. REPROCELL Main Business
Table 124. REPROCELL Latest Developments
Table 125. NEXEL Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 126. NEXEL iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 127. NEXEL iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 128. NEXEL Main Business
Table 129. NEXEL Latest Developments
Table 130. Curi Bio Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 131. Curi Bio iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 132. Curi Bio iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 133. Curi Bio Main Business
Table 134. Curi Bio Latest Developments
Table 135. Creative Bioarray Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 136. Creative Bioarray iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 137. Creative Bioarray iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 138. Creative Bioarray Main Business
Table 139. Creative Bioarray Latest Developments
Table 140. Applied StemCell Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 141. Applied StemCell iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 142. Applied StemCell iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 143. Applied StemCell Main Business
Table 144. Applied StemCell Latest Developments
Table 145. BPS Bioscience Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 146. BPS Bioscience iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 147. BPS Bioscience iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 148. BPS Bioscience Main Business
Table 149. BPS Bioscience Latest Developments
Table 150. Cell Applications Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 151. Cell Applications iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 152. Cell Applications iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 153. Cell Applications Main Business
Table 154. Cell Applications Latest Developments
Table 1. iPSC-Derived Cardiomyocytes Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. iPSC-Derived Cardiomyocytes Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Ventricular-Like Cardiomyocytes
Table 4. Major Players of Atrial-Like Cardiomyocytes
Table 5. Major Players of Nodal-Like Cardiomyocytes
Table 6. Major Players of Mixed Cardiomyocytes
Table 7. Major Players of Cardiac Progenitor-Derived Cardiomyocytes
Table 8. Global iPSC-Derived Cardiomyocytes Sales by Type (2021-2026) & (K Dose)
Table 9. Global iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
Table 10. Global iPSC-Derived Cardiomyocytes Revenue by Type (2021-2026) & ($ million)
Table 11. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Type (2021-2026)
Table 12. Global iPSC-Derived Cardiomyocytes Sale Price by Type (2021-2026) & (US$/Dose)
Table 13. Major Players of Healthy Donor Cells
Table 14. Major Players of Patient-Derived Disease Cells
Table 15. Major Players of Gene-Edited Disease Cells
Table 16. Major Players of Isogenic Control Cells
Table 17. Major Players of Custom Line-Derived Cells
Table 18. Global iPSC-Derived Cardiomyocytes Sales by Donor and Genetic Background (2021-2026) & (K Dose)
Table 19. Global iPSC-Derived Cardiomyocytes Sales Market Share by Donor and Genetic Background (2021-2026)
Table 20. Global iPSC-Derived Cardiomyocytes Revenue by Donor and Genetic Background (2021-2026) & ($ million)
Table 21. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Donor and Genetic Background (2021-2026)
Table 22. Global iPSC-Derived Cardiomyocytes Sale Price by Donor and Genetic Background (2021-2026) & (US$/Dose)
Table 23. Major Players of Cryopreserved Cell Vials
Table 24. Major Players of Plate-Ready Cells
Table 25. Major Players of Assay Kits With Media
Table 26. Major Players of 3D Cardiac Microtissues
Table 27. Major Players of Custom Differentiation Lots
Table 28. Global iPSC-Derived Cardiomyocytes Sales by Delivery Format (2021-2026) & (K Dose)
Table 29. Global iPSC-Derived Cardiomyocytes Sales Market Share by Delivery Format (2021-2026)
Table 30. Global iPSC-Derived Cardiomyocytes Revenue by Delivery Format (2021-2026) & ($ million)
Table 31. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Delivery Format (2021-2026)
Table 32. Global iPSC-Derived Cardiomyocytes Sale Price by Delivery Format (2021-2026) & (US$/Dose)
Table 33. Major Players of Standard Research Grade
Table 34. Major Players of Assay-Ready Grade
Table 35. Major Players of Electrophysiology Validated Grade
Table 36. Major Players of High-Throughput Screening Grade
Table 37. Major Players of GMP-Compatible Development Grade
Table 38. Global iPSC-Derived Cardiomyocytes Sales by Validation Grade (2021-2026) & (K Dose)
Table 39. Global iPSC-Derived Cardiomyocytes Sales Market Share by Validation Grade (2021-2026)
Table 40. Global iPSC-Derived Cardiomyocytes Revenue by Validation Grade (2021-2026) & ($ million)
Table 41. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Validation Grade (2021-2026)
Table 42. Global iPSC-Derived Cardiomyocytes Sale Price by Validation Grade (2021-2026) & (US$/Dose)
Table 43. Global iPSC-Derived Cardiomyocytes Sale by Application (2021-2026) & (K Dose)
Table 44. Global iPSC-Derived Cardiomyocytes Sale Market Share by Application (2021-2026)
Table 45. Global iPSC-Derived Cardiomyocytes Revenue by Application (2021-2026) & ($ million)
Table 46. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Application (2021-2026)
Table 47. Global iPSC-Derived Cardiomyocytes Sale Price by Application (2021-2026) & (US$/Dose)
Table 48. Global iPSC-Derived Cardiomyocytes Sales by Company (2021-2026) & (K Dose)
Table 49. Global iPSC-Derived Cardiomyocytes Sales Market Share by Company (2021-2026)
Table 50. Global iPSC-Derived Cardiomyocytes Revenue by Company (2021-2026) & ($ millions)
Table 51. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Company (2021-2026)
Table 52. Global iPSC-Derived Cardiomyocytes Sale Price by Company (2021-2026) & (US$/Dose)
Table 53. Key Manufacturers iPSC-Derived Cardiomyocytes Producing Area Distribution and Sales Area
Table 54. Players iPSC-Derived Cardiomyocytes Products Offered
Table 55. iPSC-Derived Cardiomyocytes Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 56. New Products and Potential Entrants
Table 57. Market M&A Activity & Strategy
Table 58. Global iPSC-Derived Cardiomyocytes Sales by Geographic Region (2021-2026) & (K Dose)
Table 59. Global iPSC-Derived Cardiomyocytes Sales Market Share Geographic Region (2021-2026)
Table 60. Global iPSC-Derived Cardiomyocytes Revenue by Geographic Region (2021-2026) & ($ millions)
Table 61. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Geographic Region (2021-2026)
Table 62. Global iPSC-Derived Cardiomyocytes Sales by Country/Region (2021-2026) & (K Dose)
Table 63. Global iPSC-Derived Cardiomyocytes Sales Market Share by Country/Region (2021-2026)
Table 64. Global iPSC-Derived Cardiomyocytes Revenue by Country/Region (2021-2026) & ($ millions)
Table 65. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Country/Region (2021-2026)
Table 66. Americas iPSC-Derived Cardiomyocytes Sales by Country (2021-2026) & (K Dose)
Table 67. Americas iPSC-Derived Cardiomyocytes Sales Market Share by Country (2021-2026)
Table 68. Americas iPSC-Derived Cardiomyocytes Revenue by Country (2021-2026) & ($ millions)
Table 69. Americas iPSC-Derived Cardiomyocytes Sales by Type (2021-2026) & (K Dose)
Table 70. Americas iPSC-Derived Cardiomyocytes Sales by Application (2021-2026) & (K Dose)
Table 71. APAC iPSC-Derived Cardiomyocytes Sales by Region (2021-2026) & (K Dose)
Table 72. APAC iPSC-Derived Cardiomyocytes Sales Market Share by Region (2021-2026)
Table 73. APAC iPSC-Derived Cardiomyocytes Revenue by Region (2021-2026) & ($ millions)
Table 74. APAC iPSC-Derived Cardiomyocytes Sales by Type (2021-2026) & (K Dose)
Table 75. APAC iPSC-Derived Cardiomyocytes Sales by Application (2021-2026) & (K Dose)
Table 76. Europe iPSC-Derived Cardiomyocytes Sales by Country (2021-2026) & (K Dose)
Table 77. Europe iPSC-Derived Cardiomyocytes Revenue by Country (2021-2026) & ($ millions)
Table 78. Europe iPSC-Derived Cardiomyocytes Sales by Type (2021-2026) & (K Dose)
Table 79. Europe iPSC-Derived Cardiomyocytes Sales by Application (2021-2026) & (K Dose)
Table 80. Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Country (2021-2026) & (K Dose)
Table 81. Middle East & Africa iPSC-Derived Cardiomyocytes Revenue Market Share by Country (2021-2026)
Table 82. Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Type (2021-2026) & (K Dose)
Table 83. Middle East & Africa iPSC-Derived Cardiomyocytes Sales by Application (2021-2026) & (K Dose)
Table 84. Key Market Drivers & Growth Opportunities of iPSC-Derived Cardiomyocytes
Table 85. Key Market Challenges & Risks of iPSC-Derived Cardiomyocytes
Table 86. Key Industry Trends of iPSC-Derived Cardiomyocytes
Table 87. iPSC-Derived Cardiomyocytes Raw Material
Table 88. Key Suppliers of Raw Materials
Table 89. iPSC-Derived Cardiomyocytes Distributors List
Table 90. iPSC-Derived Cardiomyocytes Customer List
Table 91. Global iPSC-Derived Cardiomyocytes Sales Forecast by Region (2027-2032) & (K Dose)
Table 92. Global iPSC-Derived Cardiomyocytes Revenue Forecast by Region (2027-2032) & ($ millions)
Table 93. Americas iPSC-Derived Cardiomyocytes Sales Forecast by Country (2027-2032) & (K Dose)
Table 94. Americas iPSC-Derived Cardiomyocytes Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 95. APAC iPSC-Derived Cardiomyocytes Sales Forecast by Region (2027-2032) & (K Dose)
Table 96. APAC iPSC-Derived Cardiomyocytes Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 97. Europe iPSC-Derived Cardiomyocytes Sales Forecast by Country (2027-2032) & (K Dose)
Table 98. Europe iPSC-Derived Cardiomyocytes Revenue Forecast by Country (2027-2032) & ($ millions)
Table 99. Middle East & Africa iPSC-Derived Cardiomyocytes Sales Forecast by Country (2027-2032) & (K Dose)
Table 100. Middle East & Africa iPSC-Derived Cardiomyocytes Revenue Forecast by Country (2027-2032) & ($ millions)
Table 101. Global iPSC-Derived Cardiomyocytes Sales Forecast by Type (2027-2032) & (K Dose)
Table 102. Global iPSC-Derived Cardiomyocytes Revenue Forecast by Type (2027-2032) & ($ millions)
Table 103. Global iPSC-Derived Cardiomyocytes Sales Forecast by Application (2027-2032) & (K Dose)
Table 104. Global iPSC-Derived Cardiomyocytes Revenue Forecast by Application (2027-2032) & ($ millions)
Table 105. FUJIFILM Cellular Dynamics Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 106. FUJIFILM Cellular Dynamics iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 107. FUJIFILM Cellular Dynamics iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 108. FUJIFILM Cellular Dynamics Main Business
Table 109. FUJIFILM Cellular Dynamics Latest Developments
Table 110. Ncardia Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 111. Ncardia iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 112. Ncardia iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 113. Ncardia Main Business
Table 114. Ncardia Latest Developments
Table 115. Axol Bioscience Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 116. Axol Bioscience iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 117. Axol Bioscience iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 118. Axol Bioscience Main Business
Table 119. Axol Bioscience Latest Developments
Table 120. REPROCELL Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 121. REPROCELL iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 122. REPROCELL iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 123. REPROCELL Main Business
Table 124. REPROCELL Latest Developments
Table 125. NEXEL Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 126. NEXEL iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 127. NEXEL iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 128. NEXEL Main Business
Table 129. NEXEL Latest Developments
Table 130. Curi Bio Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 131. Curi Bio iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 132. Curi Bio iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 133. Curi Bio Main Business
Table 134. Curi Bio Latest Developments
Table 135. Creative Bioarray Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 136. Creative Bioarray iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 137. Creative Bioarray iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 138. Creative Bioarray Main Business
Table 139. Creative Bioarray Latest Developments
Table 140. Applied StemCell Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 141. Applied StemCell iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 142. Applied StemCell iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 143. Applied StemCell Main Business
Table 144. Applied StemCell Latest Developments
Table 145. BPS Bioscience Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 146. BPS Bioscience iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 147. BPS Bioscience iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 148. BPS Bioscience Main Business
Table 149. BPS Bioscience Latest Developments
Table 150. Cell Applications Basic Information, iPSC-Derived Cardiomyocytes Manufacturing Base, Sales Area and Its Competitors
Table 151. Cell Applications iPSC-Derived Cardiomyocytes Product Portfolios and Specifications
Table 152. Cell Applications iPSC-Derived Cardiomyocytes Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 153. Cell Applications Main Business
Table 154. Cell Applications Latest Developments
LIST OF FIGURES
Figure 1. Picture of iPSC-Derived Cardiomyocytes
Figure 2. iPSC-Derived Cardiomyocytes Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global iPSC-Derived Cardiomyocytes Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global iPSC-Derived Cardiomyocytes Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. iPSC-Derived Cardiomyocytes Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. iPSC-Derived Cardiomyocytes Sales Market Share by Country/Region (2025)
Figure 10. iPSC-Derived Cardiomyocytes Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Ventricular-Like Cardiomyocytes
Figure 12. Product Picture of Atrial-Like Cardiomyocytes
Figure 13. Product Picture of Nodal-Like Cardiomyocytes
Figure 14. Product Picture of Mixed Cardiomyocytes
Figure 15. Product Picture of Cardiac Progenitor-Derived Cardiomyocytes
Figure 16. Global iPSC-Derived Cardiomyocytes Sales Market Share by Type in 2026
Figure 17. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Healthy Donor Cells
Figure 19. Product Picture of Patient-Derived Disease Cells
Figure 20. Product Picture of Gene-Edited Disease Cells
Figure 21. Product Picture of Isogenic Control Cells
Figure 22. Product Picture of Custom Line-Derived Cells
Figure 23. Global iPSC-Derived Cardiomyocytes Sales Market Share by Donor and Genetic Background in 2026
Figure 24. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Donor and Genetic Background (2021-2026)
Figure 25. Product Picture of Cryopreserved Cell Vials
Figure 26. Product Picture of Plate-Ready Cells
Figure 27. Product Picture of Assay Kits With Media
Figure 28. Product Picture of 3D Cardiac Microtissues
Figure 29. Product Picture of Custom Differentiation Lots
Figure 30. Global iPSC-Derived Cardiomyocytes Sales Market Share by Delivery Format in 2026
Figure 31. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Delivery Format (2021-2026)
Figure 32. Product Picture of Standard Research Grade
Figure 33. Product Picture of Assay-Ready Grade
Figure 34. Product Picture of Electrophysiology Validated Grade
Figure 35. Product Picture of High-Throughput Screening Grade
Figure 36. Product Picture of GMP-Compatible Development Grade
Figure 37. Global iPSC-Derived Cardiomyocytes Sales Market Share by Validation Grade in 2026
Figure 38. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Validation Grade (2021-2026)
Figure 39. iPSC-Derived Cardiomyocytes Consumed in Cardiotoxicity Testing
Figure 40. Global iPSC-Derived Cardiomyocytes Market: Cardiotoxicity Testing (2021-2026) & (K Dose)
Figure 41. iPSC-Derived Cardiomyocytes Consumed in Drug Discovery and Screening
Figure 42. Global iPSC-Derived Cardiomyocytes Market: Drug Discovery and Screening (2021-2026) & (K Dose)
Figure 43. iPSC-Derived Cardiomyocytes Consumed in Disease Modeling
Figure 44. Global iPSC-Derived Cardiomyocytes Market: Disease Modeling (2021-2026) & (K Dose)
Figure 45. iPSC-Derived Cardiomyocytes Consumed in Electrophysiology and Contractility Assays
Figure 46. Global iPSC-Derived Cardiomyocytes Market: Electrophysiology and Contractility Assays (2021-2026) & (K Dose)
Figure 47. iPSC-Derived Cardiomyocytes Consumed in Regenerative Medicine Research
Figure 48. Global iPSC-Derived Cardiomyocytes Market: Regenerative Medicine Research (2021-2026) & (K Dose)
Figure 49. iPSC-Derived Cardiomyocytes Consumed in Cardiac Tissue Engineering
Figure 50. Global iPSC-Derived Cardiomyocytes Market: Cardiac Tissue Engineering (2021-2026) & (K Dose)
Figure 51. Global iPSC-Derived Cardiomyocytes Sale Market Share by Application (2025)
Figure 52. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Application in 2025
Figure 53. iPSC-Derived Cardiomyocytes Sales by Company in 2025 (K Dose)
Figure 54. Global iPSC-Derived Cardiomyocytes Sales Market Share by Company in 2025
Figure 55. iPSC-Derived Cardiomyocytes Revenue by Company in 2025 ($ millions)
Figure 56. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Company in 2025
Figure 57. Global iPSC-Derived Cardiomyocytes Sales Market Share by Geographic Region (2021-2026)
Figure 58. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Geographic Region in 2025
Figure 59. Americas iPSC-Derived Cardiomyocytes Sales 2021-2026 (K Dose)
Figure 60. Americas iPSC-Derived Cardiomyocytes Revenue 2021-2026 ($ millions)
Figure 61. APAC iPSC-Derived Cardiomyocytes Sales 2021-2026 (K Dose)
Figure 62. APAC iPSC-Derived Cardiomyocytes Revenue 2021-2026 ($ millions)
Figure 63. Europe iPSC-Derived Cardiomyocytes Sales 2021-2026 (K Dose)
Figure 64. Europe iPSC-Derived Cardiomyocytes Revenue 2021-2026 ($ millions)
Figure 65. Middle East & Africa iPSC-Derived Cardiomyocytes Sales 2021-2026 (K Dose)
Figure 66. Middle East & Africa iPSC-Derived Cardiomyocytes Revenue 2021-2026 ($ millions)
Figure 67. Americas iPSC-Derived Cardiomyocytes Sales Market Share by Country in 2025
Figure 68. Americas iPSC-Derived Cardiomyocytes Revenue Market Share by Country (2021-2026)
Figure 69. Americas iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
Figure 70. Americas iPSC-Derived Cardiomyocytes Sales Market Share by Application (2021-2026)
Figure 71. United States iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 72. Canada iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 73. Mexico iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 74. Brazil iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 75. APAC iPSC-Derived Cardiomyocytes Sales Market Share by Region in 2025
Figure 76. APAC iPSC-Derived Cardiomyocytes Revenue Market Share by Region (2021-2026)
Figure 77. APAC iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
Figure 78. APAC iPSC-Derived Cardiomyocytes Sales Market Share by Application (2021-2026)
Figure 79. China iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 80. Japan iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 81. South Korea iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 82. Southeast Asia iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 83. India iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 84. Australia iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 85. China Taiwan iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 86. Europe iPSC-Derived Cardiomyocytes Sales Market Share by Country in 2025
Figure 87. Europe iPSC-Derived Cardiomyocytes Revenue Market Share by Country (2021-2026)
Figure 88. Europe iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
Figure 89. Europe iPSC-Derived Cardiomyocytes Sales Market Share by Application (2021-2026)
Figure 90. Germany iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 91. France iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 92. UK iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 93. Italy iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 94. Russia iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 95. Middle East & Africa iPSC-Derived Cardiomyocytes Sales Market Share by Country (2021-2026)
Figure 96. Middle East & Africa iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
Figure 97. Middle East & Africa iPSC-Derived Cardiomyocytes Sales Market Share by Application (2021-2026)
Figure 98. Egypt iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 99. South Africa iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 100. Israel iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 101. Turkey iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 102. GCC Countries iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 103. Manufacturing Cost Structure Analysis of iPSC-Derived Cardiomyocytes in 2026
Figure 104. Manufacturing Process Analysis of iPSC-Derived Cardiomyocytes
Figure 105. Industry Chain Structure of iPSC-Derived Cardiomyocytes
Figure 106. Channels of Distribution
Figure 107. Global iPSC-Derived Cardiomyocytes Sales Market Forecast by Region (2027-2032)
Figure 108. Global iPSC-Derived Cardiomyocytes Revenue Market Share Forecast by Region (2027-2032)
Figure 109. Global iPSC-Derived Cardiomyocytes Sales Market Share Forecast by Type (2027-2032)
Figure 110. Global iPSC-Derived Cardiomyocytes Revenue Market Share Forecast by Type (2027-2032)
Figure 111. Global iPSC-Derived Cardiomyocytes Sales Market Share Forecast by Application (2027-2032)
Figure 112. Global iPSC-Derived Cardiomyocytes Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of iPSC-Derived Cardiomyocytes
Figure 2. iPSC-Derived Cardiomyocytes Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global iPSC-Derived Cardiomyocytes Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global iPSC-Derived Cardiomyocytes Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. iPSC-Derived Cardiomyocytes Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. iPSC-Derived Cardiomyocytes Sales Market Share by Country/Region (2025)
Figure 10. iPSC-Derived Cardiomyocytes Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Ventricular-Like Cardiomyocytes
Figure 12. Product Picture of Atrial-Like Cardiomyocytes
Figure 13. Product Picture of Nodal-Like Cardiomyocytes
Figure 14. Product Picture of Mixed Cardiomyocytes
Figure 15. Product Picture of Cardiac Progenitor-Derived Cardiomyocytes
Figure 16. Global iPSC-Derived Cardiomyocytes Sales Market Share by Type in 2026
Figure 17. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Healthy Donor Cells
Figure 19. Product Picture of Patient-Derived Disease Cells
Figure 20. Product Picture of Gene-Edited Disease Cells
Figure 21. Product Picture of Isogenic Control Cells
Figure 22. Product Picture of Custom Line-Derived Cells
Figure 23. Global iPSC-Derived Cardiomyocytes Sales Market Share by Donor and Genetic Background in 2026
Figure 24. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Donor and Genetic Background (2021-2026)
Figure 25. Product Picture of Cryopreserved Cell Vials
Figure 26. Product Picture of Plate-Ready Cells
Figure 27. Product Picture of Assay Kits With Media
Figure 28. Product Picture of 3D Cardiac Microtissues
Figure 29. Product Picture of Custom Differentiation Lots
Figure 30. Global iPSC-Derived Cardiomyocytes Sales Market Share by Delivery Format in 2026
Figure 31. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Delivery Format (2021-2026)
Figure 32. Product Picture of Standard Research Grade
Figure 33. Product Picture of Assay-Ready Grade
Figure 34. Product Picture of Electrophysiology Validated Grade
Figure 35. Product Picture of High-Throughput Screening Grade
Figure 36. Product Picture of GMP-Compatible Development Grade
Figure 37. Global iPSC-Derived Cardiomyocytes Sales Market Share by Validation Grade in 2026
Figure 38. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Validation Grade (2021-2026)
Figure 39. iPSC-Derived Cardiomyocytes Consumed in Cardiotoxicity Testing
Figure 40. Global iPSC-Derived Cardiomyocytes Market: Cardiotoxicity Testing (2021-2026) & (K Dose)
Figure 41. iPSC-Derived Cardiomyocytes Consumed in Drug Discovery and Screening
Figure 42. Global iPSC-Derived Cardiomyocytes Market: Drug Discovery and Screening (2021-2026) & (K Dose)
Figure 43. iPSC-Derived Cardiomyocytes Consumed in Disease Modeling
Figure 44. Global iPSC-Derived Cardiomyocytes Market: Disease Modeling (2021-2026) & (K Dose)
Figure 45. iPSC-Derived Cardiomyocytes Consumed in Electrophysiology and Contractility Assays
Figure 46. Global iPSC-Derived Cardiomyocytes Market: Electrophysiology and Contractility Assays (2021-2026) & (K Dose)
Figure 47. iPSC-Derived Cardiomyocytes Consumed in Regenerative Medicine Research
Figure 48. Global iPSC-Derived Cardiomyocytes Market: Regenerative Medicine Research (2021-2026) & (K Dose)
Figure 49. iPSC-Derived Cardiomyocytes Consumed in Cardiac Tissue Engineering
Figure 50. Global iPSC-Derived Cardiomyocytes Market: Cardiac Tissue Engineering (2021-2026) & (K Dose)
Figure 51. Global iPSC-Derived Cardiomyocytes Sale Market Share by Application (2025)
Figure 52. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Application in 2025
Figure 53. iPSC-Derived Cardiomyocytes Sales by Company in 2025 (K Dose)
Figure 54. Global iPSC-Derived Cardiomyocytes Sales Market Share by Company in 2025
Figure 55. iPSC-Derived Cardiomyocytes Revenue by Company in 2025 ($ millions)
Figure 56. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Company in 2025
Figure 57. Global iPSC-Derived Cardiomyocytes Sales Market Share by Geographic Region (2021-2026)
Figure 58. Global iPSC-Derived Cardiomyocytes Revenue Market Share by Geographic Region in 2025
Figure 59. Americas iPSC-Derived Cardiomyocytes Sales 2021-2026 (K Dose)
Figure 60. Americas iPSC-Derived Cardiomyocytes Revenue 2021-2026 ($ millions)
Figure 61. APAC iPSC-Derived Cardiomyocytes Sales 2021-2026 (K Dose)
Figure 62. APAC iPSC-Derived Cardiomyocytes Revenue 2021-2026 ($ millions)
Figure 63. Europe iPSC-Derived Cardiomyocytes Sales 2021-2026 (K Dose)
Figure 64. Europe iPSC-Derived Cardiomyocytes Revenue 2021-2026 ($ millions)
Figure 65. Middle East & Africa iPSC-Derived Cardiomyocytes Sales 2021-2026 (K Dose)
Figure 66. Middle East & Africa iPSC-Derived Cardiomyocytes Revenue 2021-2026 ($ millions)
Figure 67. Americas iPSC-Derived Cardiomyocytes Sales Market Share by Country in 2025
Figure 68. Americas iPSC-Derived Cardiomyocytes Revenue Market Share by Country (2021-2026)
Figure 69. Americas iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
Figure 70. Americas iPSC-Derived Cardiomyocytes Sales Market Share by Application (2021-2026)
Figure 71. United States iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 72. Canada iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 73. Mexico iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 74. Brazil iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 75. APAC iPSC-Derived Cardiomyocytes Sales Market Share by Region in 2025
Figure 76. APAC iPSC-Derived Cardiomyocytes Revenue Market Share by Region (2021-2026)
Figure 77. APAC iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
Figure 78. APAC iPSC-Derived Cardiomyocytes Sales Market Share by Application (2021-2026)
Figure 79. China iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 80. Japan iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 81. South Korea iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 82. Southeast Asia iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 83. India iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 84. Australia iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 85. China Taiwan iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 86. Europe iPSC-Derived Cardiomyocytes Sales Market Share by Country in 2025
Figure 87. Europe iPSC-Derived Cardiomyocytes Revenue Market Share by Country (2021-2026)
Figure 88. Europe iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
Figure 89. Europe iPSC-Derived Cardiomyocytes Sales Market Share by Application (2021-2026)
Figure 90. Germany iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 91. France iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 92. UK iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 93. Italy iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 94. Russia iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 95. Middle East & Africa iPSC-Derived Cardiomyocytes Sales Market Share by Country (2021-2026)
Figure 96. Middle East & Africa iPSC-Derived Cardiomyocytes Sales Market Share by Type (2021-2026)
Figure 97. Middle East & Africa iPSC-Derived Cardiomyocytes Sales Market Share by Application (2021-2026)
Figure 98. Egypt iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 99. South Africa iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 100. Israel iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 101. Turkey iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 102. GCC Countries iPSC-Derived Cardiomyocytes Revenue Growth 2021-2026 ($ millions)
Figure 103. Manufacturing Cost Structure Analysis of iPSC-Derived Cardiomyocytes in 2026
Figure 104. Manufacturing Process Analysis of iPSC-Derived Cardiomyocytes
Figure 105. Industry Chain Structure of iPSC-Derived Cardiomyocytes
Figure 106. Channels of Distribution
Figure 107. Global iPSC-Derived Cardiomyocytes Sales Market Forecast by Region (2027-2032)
Figure 108. Global iPSC-Derived Cardiomyocytes Revenue Market Share Forecast by Region (2027-2032)
Figure 109. Global iPSC-Derived Cardiomyocytes Sales Market Share Forecast by Type (2027-2032)
Figure 110. Global iPSC-Derived Cardiomyocytes Revenue Market Share Forecast by Type (2027-2032)
Figure 111. Global iPSC-Derived Cardiomyocytes Sales Market Share Forecast by Application (2027-2032)
Figure 112. Global iPSC-Derived Cardiomyocytes Revenue Market Share Forecast by Application (2027-2032)
